Phase III trial shows noninferiority of VV116 compared to nirmatrelvir–ritonavir among adults with mild-to-moderate COVID-19 at risk of progression

Researchers presented the results of a phase III randomized controlled trial of oral SARS-CoV-2 antiviral VV116.